Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

SGLT2 inhibitors


Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.


Highlights

09-12-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

05-12-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

18-11-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

More on SGLT2 inhibitors

04-09-2023 | Type 2 diabetes | News

New model predicts kidney disease progression risk in type 2 diabetes

31-08-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and finerenone for kidney disease treatment

Ian de Boer joins Amrit Lamba to discuss how these medications will influence the treatment of kidney disease in people with DKD.

06-12-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

04-11-2022 | Empagliflozin | News | Article

EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease

24-10-2022 | Cardiovascular outcomes | News

Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

06-10-2022 | SGLT2 inhibitors | News

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

02-09-2022 | Dapagliflozin | News

DELIVER results round-up: Frailty, AF, recent hospitalization, and more

27-08-2022 | Dapagliflozin | News

Dapagliflozin DELIVERs improved HFpEF outcomes

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.
  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.
Image Credits